PL449432A1 - Kompozycja szczepionki do zastosowania w profilaktyce chorób zakaźnych - Google Patents

Kompozycja szczepionki do zastosowania w profilaktyce chorób zakaźnych

Info

Publication number
PL449432A1
PL449432A1 PL449432A PL44943222A PL449432A1 PL 449432 A1 PL449432 A1 PL 449432A1 PL 449432 A PL449432 A PL 449432A PL 44943222 A PL44943222 A PL 44943222A PL 449432 A1 PL449432 A1 PL 449432A1
Authority
PL
Poland
Prior art keywords
application
infectious diseases
vaccine composition
preventing infectious
preventing
Prior art date
Application number
PL449432A
Other languages
English (en)
Other versions
PL247223B1 (pl
Inventor
Monika Staniszewska
Joanna Baran
Łukasz Kuryk
Mariangela GAROFALO
Katarzyna Wanda Pancer
Anna Mazurkiewicz-Pisarek
Alina Mazurkiewicz
Diana MIKIEWICZ
Tomasz CIACH
Ewa Augustynowicz-Kopeć
Sylwia Brzezińska
Agnieszka Iwańska
Original Assignee
Politechnika Warszawska
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Politechnika Warszawska filed Critical Politechnika Warszawska
Priority to PL449432A priority Critical patent/PL247223B1/pl
Publication of PL449432A1 publication Critical patent/PL449432A1/pl
Publication of PL247223B1 publication Critical patent/PL247223B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL449432A 2022-10-10 2022-10-10 Kompozycja szczepionki do zastosowania w profilaktyce chorób zakaźnych PL247223B1 (pl)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL449432A PL247223B1 (pl) 2022-10-10 2022-10-10 Kompozycja szczepionki do zastosowania w profilaktyce chorób zakaźnych

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL449432A PL247223B1 (pl) 2022-10-10 2022-10-10 Kompozycja szczepionki do zastosowania w profilaktyce chorób zakaźnych

Publications (2)

Publication Number Publication Date
PL449432A1 true PL449432A1 (pl) 2024-12-02
PL247223B1 PL247223B1 (pl) 2025-06-02

Family

ID=93707004

Family Applications (1)

Application Number Title Priority Date Filing Date
PL449432A PL247223B1 (pl) 2022-10-10 2022-10-10 Kompozycja szczepionki do zastosowania w profilaktyce chorób zakaźnych

Country Status (1)

Country Link
PL (1) PL247223B1 (pl)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022013405A1 (en) * 2020-07-15 2022-01-20 Institut Pasteur Sars-cov-2 immunogenic compositions, vaccines, and methods

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022013405A1 (en) * 2020-07-15 2022-01-20 Institut Pasteur Sars-cov-2 immunogenic compositions, vaccines, and methods

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GAROFALO, M ET AL.: "Pharmaceutics. 2021; 13(4): 547", COMBINATION THERAPY OF NOVEL ONCOLYTIC ADENOVIRUS WITH ANTI-PD1 RESULTED IN ENHANCED ANTI-CANCER EFFECT IN SYNGENEIC IMMUNOCOMPETENT MELANOMA MOUSE MODEL. *
JANGRA, S ET AL.: "Front Immunol. 2021 Sep 16; 12: 729189", A COMBINATION ADJUVANT FOR THE INDUCTION OF POTENT ANTIVIRAL IMMUNE RESPONSES FOR A RECOMBINANT SARS-COV-2 PROTEIN VACCINE. *

Also Published As

Publication number Publication date
PL247223B1 (pl) 2025-06-02

Similar Documents

Publication Publication Date Title
GB202212336D0 (en) Coronavirus vaccine formulations
IL306088A (en) Vaccine formulations against coronavirus
EP4321020A4 (en) COMPOSITION OF ORAL VACCINE
SG10202104508YA (en) Immunogenic composition
EP4397316A4 (en) COMPOSITION TO IMPROVE IMMUNOGENICITY
PL449432A1 (pl) Kompozycja szczepionki do zastosowania w profilaktyce chorób zakaźnych
GB202205231D0 (en) Vaccine compositions
GB202013262D0 (en) Vaccine Composition
IL291006B1 (en) Immunogenic preparations against intestinal diseases and methods for their preparation
GB202107170D0 (en) Vaccine compositions
GB202207281D0 (en) Vaccine
IL285526A (en) A live attenuated influenza vaccine preparation and a process for its preparation
IL324224A (en) A vaccine containing an antibody against NGF
SI4021505T1 (sl) Zdravilo za zdravljenje nalezljivih bolezni
IL320790A (en) Low-dose vaccines
IL324118A (en) Vaccines against sars-cov-2
GB202314361D0 (en) Vaccine compositions and uses thereof
GB202317903D0 (en) Vaccine formulation
HK40096991A (zh) 用於预防sars-cov-2的疫苗组合物
GB202015984D0 (en) Vaccine compositions
AU2021900689A0 (en) Improved vaccine composition
IL323587A (en) Method for producing viral vaccines and preparations containing them
GB202510395D0 (en) Vaccine
GB202318238D0 (en) Vaccine
GB202301244D0 (en) Vaccine